ArticleOpen veterinary journal2025
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Atherosclerosis is often associated with inflammation and non-alcoholic liver disease due to high-cholesterol diet and the side effects of conventional treatment. Aim: This study aimed to determine the efficacy of Methods: Hypercholesterolemia induction was achieved by oral administration of feed with lard for 21 days in male Wistar rats. Next, the animals were treated with 4 mg/kg BW of BBLE (single dose) and 4 mg/kg BW of BBLE+SAE (combined dose) for 3 months, and continued to be given a high cholesterol diet. The negative control was a high cholesterol diet, and the positive control was simvastatin. Blood samples were taken to determine total cholesterol, apolipoprotein-E (Apo-E), interleukin-6, tumor necrosis factor-α, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels. Meanwhile, the weight of the liver and histopathology preparations were weighed. Results: Giving BBLE+SAE was able to reduce body weight, liver weight, and cholesterol levels significantly compared to negative controls ( Conclusion: Administration of BBLE+SAE acts as an anti-atherosclerotic and hepatoprotective agent for the liver through reducing pro-inflammatory cytokines, and its use was promising for clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.